10-Q: NewAmsterdam Pharma Reports Q3 Loss Amid R&D Shifts

NewAmsterdam Pharma reported a significant increase in net loss for Q3 2025, driven by decreased revenue and warrant fair value changes, despite reduced R&D expenses.

Summary

• Net loss for the three months ended September 30, 2025, increased to $72.0 million from $16.6 million in the prior year, primarily due to a 99% decrease in revenue and a negative fair value change in warrants.
• Revenue for Q3 2025 was $0.3 million, down from $29.1 million in Q3 2024, largely due to no clinical development milestones being earned in the current quarter compared to $27.3 million in the prior year.
• Research and development expenses decreased by 13% to $31.0 million for Q3 2025, mainly due to the completion of several Phase 3 clinical trials in H2 2024 and cost phasing in ongoing trials.
• Selling, general and administrative expenses increased by 33% to $24.5 million for Q3 2025, driven by higher personnel expenses, including share-based compensation, and commercial preparedness activities.
• For the nine months ended September 30, 2025, net loss decreased to $128.9 million from $149.4 million in the prior year, benefiting from a gain in earnout fair value and lower warrant losses.
• Cash, cash equivalents, and marketable securities totaled $756.0 million as of September 30, 2025, a decrease from $771.7 million in cash and cash equivalents at December 31, 2024.
• The European Medicines Agency (EMA) validated Marketing Authorization Applications (MAAs) for obicetrapib monotherapy and fixed-dose combination in August 2025.
• A Supply Agreement with A. Menarini International Licensing S.A. was entered into on August 12, 2025, for commercial supply of obicetrapib products in Europe.
• The earnout milestone triggering event from the Business Combination Agreement occurred in March 2025, resulting in the issuance of 1,743,136 Ordinary Shares and full settlement of the derivative earnout liability.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significant increase in quarterly net loss and a sharp decline in revenue, primarily from the absence of milestone payments. While R&D expenses decreased and the nine-month loss improved, the quarterly performance and negative fair value changes in warrants are concerning. Positive developments like EMA validation are long-term but don't offset the immediate financial downturn.

Positives

• EMA validated Marketing Authorization Applications for obicetrapib monotherapy and fixed-dose combination, a key step towards potential European market approval.
• Net loss for the nine months ended September 30, 2025, decreased by $20.5 million compared to the same period in 2024, indicating some improvement in overall financial performance over the longer term.
• Interest income significantly increased by 52% for Q3 2025 and 70% for the nine months ended September 30, 2025, reflecting higher cash balances and interest rates.
• The derivative earnout liability was settled in full in March 2025, removing a significant liability from the balance sheet and resulting in a $4.0 million gain for the nine-month period.
• Research and development expenses decreased by 13% in Q3 2025 and 11% for the nine months ended September 30, 2025, primarily due to the completion of several Phase 3 clinical trials.

Negatives

• Net loss for the three months ended September 30, 2025, significantly increased to $72.0 million from $16.6 million in Q3 2024.
• Revenue for Q3 2025 plummeted by 99% to $0.3 million, primarily due to the absence of clinical development milestone revenue compared to the prior year.
• The fair value change in warrants resulted in a $23.8 million loss for Q3 2025, a substantial negative swing from a $4.6 million gain in Q3 2024.
• Cash and cash equivalents decreased significantly to $538.4 million as of September 30, 2025, from $771.7 million at December 31, 2024.
• Selling, general and administrative expenses increased substantially by 33% in Q3 2025 and 60% for the nine months ended September 30, 2025, indicating rising operational costs.

Risks

• Current and future legislation and executive actions affecting the healthcare industry, including healthcare reform, may impact the business and increase limitations on reimbursement, rebates, and other payments, adversely affecting third-party coverage of products.
• The Inflation Reduction Act (IRA) may reduce prices and reimbursement for products, potentially subjecting obicetrapib to price-capped negotiation under Medicare Part B and Part D if approved and not falling under statutory exclusions.
• The IRA establishes a rebate obligation for drug manufacturers that increase prices of Medicare Part B and Part D covered drugs at a rate greater than inflation.
• The IRA eliminates the Medicare Part D 'donut hole' beginning in 2025, requiring manufacturers to subsidize 10% of Part D enrollees' prescription costs below the out-of-pocket maximum and 20% once the maximum is reached, potentially increasing cost-sharing responsibility.
• Policy uncertainty regarding drug pricing, including potential 'most-favored-nation' pricing and tariffs on imported pharmaceuticals, could limit commercial opportunities and negatively impact revenues.
• Proposals by the EU Commission to amend the pharmaceutical regulatory framework could shorten periods of regulatory and/or marketing protections for innovative products, adversely affecting commercial viability in the EU.
• Changes in U.S. government policies, including increased tariffs on imported materials and goods, could raise production costs and disrupt the supply chain, adversely affecting clinical development activities.
• The company expects to continue incurring significant losses for the foreseeable future as it invests in clinical and preclinical development programs.
• The exercise of outstanding warrants is highly dependent on the price of the company's Ordinary Shares, and there is no assurance that warrants will be 'in the money' prior to expiration, potentially yielding no additional cash proceeds.

Future Outlook

The PREVAIL Phase 3 cardiovascular outcomes trial, which completed enrollment in April 2024, is expected to conclude no earlier than the end of 2026, but will likely continue beyond this point until the target number of MACE events occur. The company intends to commercialize obicetrapib in the United States themselves, if approved, and will consider additional partners for jurisdictions outside of the United States and the European Union, including Japan and China. They are also continually evaluating potential acquisitions or licenses of new product candidates.

Management Comments

• "We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated."
• "We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (LDL-C) lowering therapy."
• "We believe that obicetrapib has the potential to be a once-daily oral CETP inhibitor for lowering LDL-C, if approved."
• "Our goal is to develop and commercialize an LDL-C lowering monotherapy and a fixed-dose combination therapy, which offers the advantage of a single, low dose, once-daily oral pill, and fulfills the significant unmet need for an effective and convenient LDL-C lowering therapy."
• "We expect to continue to incur significant losses for the foreseeable future."

Industry Context

The company operates in the cardiometabolic disease sector, focusing on LDL-C lowering therapies. This industry faces a significant unmet need for effective, well-tolerated, and convenient oral treatments, as many patients do not achieve target LDL-C levels with existing statin therapies alone. The market is also influenced by a strong patient preference for oral drugs over injectable therapies. Regulatory and legislative changes, such as the Inflation Reduction Act (IRA) in the U.S. and proposed EU pharmaceutical reforms, are increasing scrutiny on drug pricing and potentially shortening market protection periods, which could impact commercial opportunities for new therapies like obicetrapib. The company's strategy to commercialize in the U.S. directly while partnering in Europe (Menarini) and seeking partners in Asia reflects a common approach for biopharmaceutical companies navigating diverse global markets and regulatory landscapes.

Comparison to Industry Standards

• Obicetrapib's demonstrated reductions in LDL-C, lipoprotein (a) (Lp(a)), and small LDL particles in Phase 3 trials (BROADWAY, BROOKLYN, TANDEM) are consistent with the efficacy seen in other LDL-C lowering drugs, including the REVEAL trial with anacetrapib, which showed MACE benefit.
• The observed 21% reduction in the exploratory MACE endpoint in the BROADWAY trial, while exploratory, aligns with the industry's focus on MACE benefit as a critical outcome for cardiovascular therapies.
• The company's development of an oral, once-daily therapy addresses the industry trend and patient preference for oral drugs over injectable therapies, with over 75% of ASCVD and HeFH outpatients preferring oral options.
• The company's reliance on third-party contract development and manufacturing organizations (CDMOs) for manufacturing is a standard practice in the biopharmaceutical industry, particularly for companies in the late-stage development phase without in-house large-scale manufacturing capabilities.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not party to any material pending legal proceedings. From time to time, it may be involved in legal proceedings arising in the ordinary course of business.

Related Party Transactions

• In the ordinary course of business, the company may enter into transactions with entities associated with a related party. These transactions are reviewed quarterly and have not been material to the consolidated financial statements to date.

Stakeholder Impact

• **Shareholders:** Experience increased net loss for the quarter, but a reduced net loss for the nine-month period. The EMA MAA validation could be a positive long-term catalyst, while the decline in cash and fair value warrant loss are short-term concerns. Executive trading plans indicate potential future share sales.
• **Employees:** Share-based compensation arrangements are a significant component of personnel expenses, indicating ongoing incentives. The Sell-to-Cover Agreements for RSUs provide a mechanism for managing tax liabilities on equity awards.
• **Customers (Menarini):** The Supply Agreement ensures commercial supply of obicetrapib products for European distribution, strengthening the partnership and potential market entry.
• **Regulatory Authorities:** The EMA's validation of MAAs signifies progress in the regulatory pathway for obicetrapib in Europe. The company is subject to evolving U.S. and EU healthcare regulations, including drug pricing and market protection, which could impact future commercialization.

Next Steps

• Continue the PREVAIL Phase 3 cardiovascular outcomes trial until the target number of MACE events occur, with an earliest conclusion date of end of 2026, likely extending beyond.
• Pursue regulatory approval for obicetrapib in the United States for commercialization.
• Consider additional partnerships for commercialization in jurisdictions outside of the United States and the European Union, including Japan and China.
• Evaluate potential acquisition or license of new product candidates to expand the pipeline.
• Monitor and respond to ongoing legislative and regulatory proposals in the healthcare industry, particularly those related to drug pricing and market protection periods.

Key Dates

Recommendation

The company presents a mixed financial picture. While the Q3 2025 net loss significantly widened due to a sharp drop in revenue and negative warrant fair value changes, the nine-month net loss improved, and R&D expenses decreased. The EMA's validation of Marketing Authorization Applications for obicetrapib is a crucial positive development, signaling progress towards commercialization in Europe. However, the company continues to incur substantial losses and faces significant regulatory and market risks, particularly concerning drug pricing and market access. The current cash position is strong, but future capital raises may be necessary. Given the early stage of commercialization, ongoing clinical trials, and regulatory uncertainties, a 'hold' recommendation is appropriate. Investors should monitor the PREVAIL trial results, regulatory approvals, and the impact of evolving healthcare policies.

Keywords

Obicetrapib, Cardiometabolic Diseases, LDL-C Lowering, CETP Inhibitor, Phase 3 Clinical Trials, EMA Marketing Authorization, Menarini Partnership, Biopharmaceutical, SEC Filing, 10-Q, Drug Development, Risk Factors